New Anticoagulants for the Prevention of Deep Venous Thrombosis: Time to Consider Cost Effectiveness?

Author： Apostolakis Stavros   Shantsila Eduard   Lip Gregory Y.H.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.27, Iss.10, 2009-10, pp. : 793-795

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Do physicians consider cost effectiveness in clinical practice?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 301, 2001-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The Dilemma of New Drugs: Are Costs Rising Faster than Effectiveness?

By Mason J.   Freemantle N.  

PharmacoEconomics, Vol. 13, Iss. 6, 1998-06 ,pp. : 653-657

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Bemiparin Sodium versus Unfractionated Heparin and Oral Anticoagulants in the Acute and Long-Term Treatment of Deep Vein Thrombosis

By Gómez-Outes Antonio  

PharmacoEconomics, Vol. 24, Iss. 1, 2006-01 ,pp. : 81-92

Adis International

Access to resources Recommend Favorite

Immunosuppressants: Cerebral venous sinus thrombosis?: case report

By  

Reactions Weekly, Vol. 1, Iss. 1297, 2010-01 ,pp. : 31-31

Adis International

Access to resources Recommend Favorite

Anticoagulation for Stroke Prevention: High Effectiveness, More Cost Benefit?

By Shantsila Eduard   Watson Timothy   Lip Gregory Y.H.  

PharmacoEconomics, Vol. 24, Iss. 10, 2006-01 ,pp. : 1035-1038

Adis International

Access to resources Recommend Favorite